Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Withdrawn 1Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Lymphoid 1CNS 1

Conditions

Brain Neoplasms 276Glioblastoma 250Glioma 156Astrocytoma 99Central Nervous System Neoplasms 70Gliosarcoma 69Oligodendroglioma 63Neuroblastoma 63Neoplasms 52Breast Neoplasms 44Melanoma 42Carcinoma, Non-Small-Cell Lung 38Neoplasm Metastasis 33Medulloblastoma 30Lymphoma 29Recurrence 28Lung Neoplasms 27Ependymoma 24Sarcoma 20Ovarian Neoplasms 19Lymphoma, Follicular 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Meningioma 18Lymphoma, Non-Hodgkin 18Leukemia 18Meningeal Carcinomatosis 17Burkitt Lymphoma 17Multiple Myeloma 16Lymphoma, Large B-Cell, Diffuse 16Diffuse Intrinsic Pontine Glioma 15

Interventions

XENP 1595 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Inflammation × CNS × Clear all
NCT05522387 2026-02-27

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Inmune Bio, Inc.

Phase 2 Terminated
11 enrolled
CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Tauopathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡